AU2003303019A1 - Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor - Google Patents

Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor

Info

Publication number
AU2003303019A1
AU2003303019A1 AU2003303019A AU2003303019A AU2003303019A1 AU 2003303019 A1 AU2003303019 A1 AU 2003303019A1 AU 2003303019 A AU2003303019 A AU 2003303019A AU 2003303019 A AU2003303019 A AU 2003303019A AU 2003303019 A1 AU2003303019 A1 AU 2003303019A1
Authority
AU
Australia
Prior art keywords
clathrates
ziprasidone
salts
soluble
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003303019A
Inventor
Yongchu Bao
Qinghua Chen
Wen Qu
Huilin Shi
Qiang Sui
Xiaomei Wang
Baoquan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry filed Critical Shanghai Institute of Pharmaceutical Industry
Publication of AU2003303019A1 publication Critical patent/AU2003303019A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003303019A 2002-12-17 2003-11-18 Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor Abandoned AU2003303019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB021551391A CN1255105C (en) 2002-12-17 2002-12-17 Water soluble dressing materials of ziracitone and its salts and their preparation
CN02155139.1 2002-12-17
PCT/CN2003/000979 WO2004054621A1 (en) 2002-12-17 2003-11-18 Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor

Publications (1)

Publication Number Publication Date
AU2003303019A1 true AU2003303019A1 (en) 2004-07-09

Family

ID=4752571

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003303019A Abandoned AU2003303019A1 (en) 2002-12-17 2003-11-18 Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor

Country Status (3)

Country Link
CN (1) CN1255105C (en)
AU (1) AU2003303019A1 (en)
WO (1) WO2004054621A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
CN100391458C (en) * 2006-02-07 2008-06-04 上海医药工业研究院 Preparation method of ziprasidone or its salt inclusion
CN102234273B (en) * 2010-04-21 2015-08-05 上海医药工业研究院 Ziprasidone mesylate semihydrate and preparation method thereof
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
TW349870B (en) * 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
UA57734C2 (en) * 1996-05-07 2003-07-15 Пфайзер Інк. Arylheterocyclic inclusion complexes

Also Published As

Publication number Publication date
WO2004054621A1 (en) 2004-07-01
CN1424037A (en) 2003-06-18
CN1255105C (en) 2006-05-10

Similar Documents

Publication Publication Date Title
AU2003251858A1 (en) Microbubble compositions, and methods for preparing and using same
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003236527A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2003270015A1 (en) Compounds, compositions, and methods
AU2002348877A1 (en) Linked authentication protocols
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
AU2002338336A1 (en) Epothilone derivatives and methods for making and using the same
AU2003299612A1 (en) Compounds, compositions and methods
AU2003266194A1 (en) Nanocomposite, method for production and use thereof
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
AU2003301066A1 (en) Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same
AU2003226751A1 (en) Low water-soluble venlafaxine salts
AU2003219100A1 (en) Pyrazolopyridazine derivatives, process for preparation and use for the inhibition of gsk-3
AU2003231352A1 (en) Biocidal formulation and methods for the preparation thereof
AU2003260984A1 (en) S-(-)-amlodipine nicotinate and process for the preparation thereof
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
AU2003303019A1 (en) Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor
AU2003267281A1 (en) Paper compositions, imaging methods and methods for manufacturing paper
AU2003267169A1 (en) Compounds, compositions and methods
AU2002953252A0 (en) Compositions, Compounds and Methods for their Preparation
AU2003281698A1 (en) 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
AU2003300262A1 (en) Phthalimidylazo dyes, processes for the preparation thereof and the use thereof
AU2003220931A1 (en) 2-pyrone compounds and use thereof
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase